Adaptive Pharmacogenomics, LLC

Researchers at the Translational Genomics Research Institute, the Van Andel Research Institute and the Virginia G. Piper Cancer Center at Scottsdale Healthcare have discovered a biomarker that could help in the treatment of patients with an aggressive type of lung cancer.

Lancet.

Curr Drug Metab. 2010 Jan;11(1):115-28

Authors: Lal S, Mahajan A, Chen WN, Chowbay B

Increased understanding of the molecular mechanisms of tumor heterogeneity combined with rapid advances in the field of pharmacogenetics and pharmacogenomics have fuelled studies on individualizing anticancer therapy.

Expert Rev Cardiovasc Ther. 2010 Mar;8(3):359-72

Authors: Aquilante CL

The sulfonylureas stimulate insulin release from pancreatic beta cells, and have been a cornerstone of Type 2 diabetes pharmacotherapy for over 50 years. Although sulfonylureas are effective antihyperglycemic agents, interindividual variability exists in drug response (i. e. , pharmacodynamics), disposition (i. e.

Expert Rev Cardiovasc Ther. 2010 Mar;8(3):339-43

Authors: Grant RW, Wexler DJ

Continuing advances in genetic discovery have uncovered several dozen loci that are associated with Type 2 diabetes, including genetic variants that appear to modify responses to commonly prescribed diabetes medications.

Researchers have discovered precisely why strands of some fluids containing long molecules called polymers form beads when stretched, findings that could be used to improve industrial processes and for administering drugs in "personalized medicine."

On my other blog, I discuss Stanford Medical School’s recent decision to offer an elective class in which students may optionally (for $99) get 1 million genetic markers measured for themselves, and then use these (or a standard reference one, if they decline) to learn about genomics. I think this is great. I am lecturing on pharmacogenomics. Go Stanford!

( from http://www. rxpgnews. com ) When someone suffers a stroke, time is critical--more than a million brain cells die each minute, starved of nourishment due to critical damage in a cerebral blood vessel.

Now, researchers have developed a new tool for efficiently removing blood clots in the brain, the leading cause of strokes.

Researchers at the Harvard School of Public Health have found that children and adolescents living in non-smoking homes in counties with laws promoting smoke-free public places have significantly lower levels of a common biomarker of secondhand smoke exposure than those living in counties with no smoke-free laws.

AMG 386 Treatment Response Increased With Dose And Exposure AMG 386 Moving Into Phase 3 For Recurrent Ovarian Cancer Separately, Two Analyses Provide Evidence Of Biomarker As Predictor Of Tumor Response To Motesanib THOUSAND OAKS, Calif. , June 6, 2010 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) today announced that AMG 386, combined with paclitaxel, demonstrated antitumor activity in a randomized Phase 2 trial involving 161 patients with recurrent ovarian cancer.   The results are being presented for the first time in an oral presentation at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting.